BerGenBio to Participate in Investor Webcast and Q&A
- Artic Securities and Carnegie will host the event on Friday, June 2, 2023, at 11:00 a.m. CEST - BERGEN, Norway, May 30, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will participate in an investor webcast and Q&A session hosted by Arctic Securities and Carnegie on Friday, June 2, 2023, at 11:00 a.m. CEST. Chief Executive Officer Martin Olin and Chief Financial Officer Rune Skeie are scheduled to attend and discuss BerGenBio’s